BRIEF-Vera Therapeutics Says ORIGIN Phase 2b Trial Met Primary And Secondary Endpoints With Significant Proteinuria Reductions

Reuters
27 Oct 2024

Oct 26 (Reuters) - Vera Therapeutics Inc :

* VERA THERAPEUTICS ANNOUNCES 96-WEEK EGFR STABILIZATION IN ORIGIN PHASE 2B STUDY OF ATACICEPT IN IGAN IN A LATE-BREAKING ORAL PRESENTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2024

* VERA THERAPEUTICS INC - PIVOTAL ORIGIN 3 TRIAL ON TRACK TO ANNOUNCE TOPLINE RESULTS IN Q2 2025, WITH PLANNED BLA SUBMISSION TO U.S. FDA LATER IN YEAR

* VERA THERAPEUTICS INC - TRIAL MET PRIMARY AND SECONDARY ENDPOINTS WITH SIGNIFICANT PROTEINURIA REDUCTIONS

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10